Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

41. Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. Full Text available with Trip Pro

Effectiveness of an Interventional Package on the Level of Anxiety, Depression, and Fatigue among Patients with Cervical Cancer. To evaluate the effectiveness of interventional package on the level of anxiety, depression, and fatigue.The study was conducted in room no. 5, first floor, B Block, Department of Radiotherapy, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh Quasi experimental pretest-posttest design was used in the study. A total of 60 patients (...) receiving radiotherapy/chemotherapy were assigned in two groups of 30 each, through total enumeration sampling technique. The tools used for the study were Zung Anxiety Scale, Beck Depression inventory, and Fatigue Scale. The protocol used for the study includes the Jacobson's Progressive muscle relaxtion technique, counsling and home care techniques.Sociodemographic variables and clinical profile of participants in both groups were comparable. Interventional package significantly reduces the anxiety

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

42. The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. (Abstract)

The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. Most guidelines for major depressive disorder recommend initial treatment with either a second-generation antidepressant (SGA) or cognitive behavioral therapy (CBT). Although most trials suggest that these treatments have similar efficacy, their health economic implications are uncertain.To quantify (...) the cost-effectiveness of CBT versus SGA for initial treatment of depression.Decision analytic model.Relative effectiveness data from a meta-analysis of randomized controlled trials; additional clinical and economic data from other publications.Adults with newly diagnosed major depressive disorder in the United States.1 to 5 years.Health care sector and societal.Initial treatment with either an SGA or group and individual CBT.Costs in 2014 U.S. dollars, quality-adjusted life-years (QALYs

2019 Annals of Internal Medicine

43. Psychosocial interventions for preventing and treating depression in dialysis patients. (Abstract)

Psychosocial interventions for preventing and treating depression in dialysis patients. People with end-stage kidney disease (ESKD) treated with dialysis are frequently affected by major depression. Dialysis patients have prioritised depression as a critically important clinical outcome in nephrology trials. Psychological and social support are potential treatments for depression, although a Cochrane review in 2005 identified zero eligible studies. This is an update of the Cochrane review first (...) published in 2005.To assess the effect of using psychosocial interventions versus usual care or a second psychosocial intervention for preventing and treating depression in patients with ESKD treated with dialysis.We searched Cochrane Kidney and Transplant's Register of Studies up to 21 June 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings

2019 Cochrane

44. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts

Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts Running head: APA GUIDELINE FOR THE TREATMENT OF DEPRESSION i Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts American Psychological Association Guideline Development Panel for the Treatment of Depressive Disorders Adopted as APA Policy Feb. 16, 2019 Author Notes Members of the Guideline Development Panel for the Treatment of Depressive Disorders were John R. McQuaid (chair (...) First Street, NE, Washington, DC 20002-4242. E-mail: cpg@apa.org. APA GUIDELINE FOR THE TREATMENT OF DEPRESSION ii Abstract The American Psychological Association (APA) developed this clinical practice guideline to provide recommendations for the treatment of depressive disorders (including major depression, subsyndromal depression, and persistent depressive disorder). It addresses three developmental cohorts: children and adolescents; general adults; and older adults (ages 60 and over). Ten

2019 American Psychological Association

45. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial Full Text available with Trip Pro

Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial Patients with acute coronary syndrome (ACS) and elevated depressive symptoms are at increased risk for recurrent cardiovascular events and mortality, worse quality of life, and higher health care costs. These observational findings prompted multiple scientific panels to advise universal depression screening in survivors of ACS prior to evidence from randomized screening (...) trials.To determine whether systematically screening for depression in survivors of ACS improves quality of life and depression compared with usual care.A 3-group multisite randomized trial enrolled 1500 patients with ACS from 4 health care systems between November 1, 2013, and March 31, 2017, with follow-up ending July 31, 2018. Patients were eligible if they had been hospitalized for ACS in the previous 2 to 12 months and had no prior history of depression. All analyses were performed on an intention

2019 EvidenceUpdates

46. Interest in participation of the development of a core outcome set for treatment of perinatal depression

Interest in participation of the development of a core outcome set for treatment of perinatal depression Interest in participation of the development of a core outcome set for treatment of perinatal depression We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Interest in participation of the development of a core outcome set for treatment (...) of perinatal depression Share: Reading time approx. 4 minutes SBU is developing a Core Outcome Set on treatment of perinatal depression and we would like your help! Perinatal depression is depression experienced during pregnancy (known as ante or prenatal depression) or after childbirth (known as postnatal depression). A more detailed description of the project is available in the . This project has been registered in the A Core Outcome Set (COS) is an agreed minimum set of outcomes or outcome measures

2019 Swedish Council on Technology Assessement

47. Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major (...) Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Last updated: March 19, 2019 Project Number: OP0534-000 Product Line: Research Type: Device Result type: Report Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological

2019 CADTH - Optimal Use

48. Esketamine for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression Esketamine for Treatment-Resistant Depression | CADTH.ca CADTH Document Viewer Esketamine for Treatment-Resistant Depression Table of Contents Search this document Esketamine for Treatment-Resistant Depression April 2019 Summary Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant (...) pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more challenging depressive disorder to treat and available therapies are often limited by significant psychological and physiological side effects. Esketamine is the S-enantiomer of racemic ketamine and is being developed as a nasal spray device for potential therapeutic use in patients with TRD. It has not yet been approved in any country but is under priority review at Health Canada

2019 CADTH - Issues in Emerging Health Technologies

49. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update

Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update | CADTH.ca Find the information you need Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines (...) – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Last updated: June 28, 2019 Project Number: RC1142-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of repetitive transcranial magnetic stimulation for patients with treatment-resistant depression? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

50. Bright Light Therapy for Depression: Clinical Effectiveness

Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness | CADTH.ca Find the information you need Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness Last updated: August 28, 2019 Project Number: RB1391-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of bright (...) light therapy in patients with major depressive disorder or persistent depressive disorder? Key Message One systematic review, and two randomized controlled trials were identified regarding the clinical effectiveness of bright light therapy in patients with major depressive disorder or persistent depressive disorder. Files Rapid Response Summary of Abstracts Published : August 28, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

52. Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis

Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis | CADTH.ca Find the information you need Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Last updated: June 11, 2019 Project Number: HE0022-000 Product Line: Technology Review Research Type: Drug Result type: Report (...) Expected Completion Date: October 28, 2019 Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Over the past decades, multiple classes of antidepressant drugs have been developed to treat this condition. The relative effectiveness and safety of antidepressants are uncertain. This project will review a recently published network meta-analysis featuring broad comparisons of several oral antidepressants for MDD. Implications for decision-making

2019 CADTH - Technology Review

53. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT Full Text available with Trip Pro

Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue

2019 NIHR HTA programme

54. A newly designed intensive caregiver education program reduces cognitive impairment, anxiety, and depression in patients with acute ischemic stroke. Full Text available with Trip Pro

A newly designed intensive caregiver education program reduces cognitive impairment, anxiety, and depression in patients with acute ischemic stroke. This study aimed to evaluate the effect of a newly designed intensive caregiver education program (ICEP) on reducing cognitive impairment, anxiety, and depression in acute ischemic stroke (AIS) patients. One hundred and ninety-six AIS patients were divided into ICEP group and Control group in a 1:1 ratio using blocked randomization method (...) . In the ICEP group, the caregivers received ICEP, while in the Control group caregivers received usual education and guidance. All patients received conventional rehabilitation treatment. Cognitive impairment (assessed by Mini Mental State Examination (MMSE) score and Montreal Cognitive Assessment (MoCA) score), anxiety (assessed by Hospital Anxiety and Depression Scale (HADS)-A score and Self-rating Anxiety Scale (SAS) score), and depression (assessed by HADS-D score and Self-rating Depression Scale (SDS

2019 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas Controlled trial quality: uncertain

55. Trial of SAGE-217 in Patients with Major Depressive Disorder. Full Text available with Trip Pro

Trial of SAGE-217 in Patients with Major Depressive Disorder. Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.In this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo (...) once daily. The primary end point was the change from baseline to day 15 in the score on the 17-item Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores indicating more severe depression). Secondary efficacy end points, which were assessed on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline in scores on additional depression and anxiety scales, a reduction from baseline of more than 50% in the HAM-D score, a HAM-D score of 7

2019 NEJM

56. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission.To determine the clinical effects of continuing antipsychotic medication once an episode of psychotic depression has responded (...) to combination treatment with an antidepressant and antipsychotic agent.Thirty-six week randomized clinical trial conducted at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remission of psychosis and remission or near-remission of depressive symptoms for 8 weeks before entering the clinical trial. The study was conducted from November 2011 to June 2017, and the final

2019 JAMA Controlled trial quality: predicted high

57. Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study Full Text available with Trip Pro

Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Third sector support workers can deliver a psychosocial intervention to older people with anxiety and depression, and it was feasible to recruit patients, but further development of recruitment strategies is needed. {{author}} {{($index , , , , , , , , , , & . Heather Burroughs 1 , Bernadette Bartlam 1 , Peter

2019 NIHR HTA programme

58. Effect of couple-based cognitive behavioural intervention on prevention of postnatal depression: multisite randomised controlled trial (Abstract)

Effect of couple-based cognitive behavioural intervention on prevention of postnatal depression: multisite randomised controlled trial To compare a couple-based cognitive behavioural intervention (CBI) for postnatal depression with CBI delivered to women alone and control (standard perinatal care).Multisite randomised controlled trial.Antenatal clinics at three regional public hospitals in Hong Kong.388 low-risk childbearing couples.Childbearing couples were randomly allocated to couple-based (...) CBI (n = 134), women-alone CBI (n = 124) or control (n = 130). The CBI consists of a 3-hour antenatal group session and two 30-minute postnatal telephone follow-up sessions.The primary outcome was depressive symptoms, measured on the Edinburgh Postnatal Depression Scale (EPDS). Assessments were collected at baseline (during pregnancy), 6 weeks, 6 months, and 12 months postpartum.Depressive symptoms were significantly more improved at 6 weeks postpartum for mothers in couple-based CBI than in women

2019 EvidenceUpdates

59. Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial Full Text available with Trip Pro

Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial The comorbidity between chronic pain and emotional problems has proven difficult to address with current treatment options. This study addresses the efficacy of a transdiagnostic emotion-focused exposure treatment ("hybrid") for chronic pain patients with comorbid emotional problems. Adults (n = 115) with chronic musculoskeletal pain (...) ) and pain interference (d = 0.63) and significantly better follow-up outcomes on depression (d = 0.43) and pain interference (d = 0.51). There were no differences on anxiety and pain intensity. Observed proportions of clinically significant improvement favoured the hybrid on all but one comparison, but no statistically significant differences were observed. We conclude that the hybrid emotion-focused treatment may be considered an acceptable, credible, and efficacious treatment option for chronic pain

2019 EvidenceUpdates

60. Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. Full Text available with Trip Pro

Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. In the search for novel treatments for depression, ketamine has emerged as a unique agent with rapid antidepressant effects. Experimental tasks involving emotional processing can be used during functional magnetic resonance imaging scanning to investigate ketamine's effects on brain function in major depressive disorder (MDD). This study examined ketamine's

2019 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain